Contents of Supplementary Tables from DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming
Ilaria Gritti(Broad Institute), Nabeel Bardeesy(Broad Institute), Marc N. Wein(Harvard University), Taranjit S. Gujral(University of Washington), Joel Markus Vaz(Fred Hutch Cancer Center), Songli Zhu(Fred Hutch Cancer Center), Prabhat Kattel(Broad Institute), John D. Gordan(University of California, San Francisco), Vanessa S. Silveira(Universidade de Ribeirão Preto), Vajira Weeresekara(Brigham Young University), Meng‐Ju Wu(Broad Institute), Phuong Vu(Harvard University), Ashwin V. Kammula(Broad Institute), Krushna C. Patra(University of Cincinnati), Vindhya Vijay(Broad Institute), Jun Qi, Giuseppe Tarantino(Ospedali Riuniti di Ancona), Robert T. Manguso(Broad Institute), Tenna Holgersen Bryde(University of Copenhagen), David Liu(Broad Institute), Marina Chan(Fred Hutch Cancer Center), Jinkai Wan(Massachusetts General Hospital), Christopher J. Ott(Broad Institute), Kei Sakamoto(University of Copenhagen)
Cited by 0
Related Papers
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
|Cell|2018|1.4k
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
|Nature Medicine|2019|1.1k